Glaukos vs TransMedics Group
TransMedics Group reported revenue of $606 million in fiscal 2025, 1.2 times Glaukos' $507 million in fiscal 2025. Glaukos' revenue grew 32.3% in its latest year, and TransMedics Group's grew 37.1%. Glaukos had an operating margin of -39.3%, against 17.9% at TransMedics Group. Free cash flow was −$22 million at Glaukos and $134 million at TransMedics Group.
Side by side
| Glaukos | TransMedics Group | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $507M | $606M |
| Revenue growth | 32.3% | 37.1% |
| Revenue growth a year, last 5 years | 17.7% | 88.3% |
| Gross margin | 55.7% | 59.9% |
| Operating margin | −39.3% | 17.9% |
| Net margin | −37.0% | 31.4% |
| Free cash flow | −$22M | $134M |
| Free cash flow margin | −4.4% | 22.1% |
| Return on capital | — | 27.5% |
| Net debt to EBITDA | — | −0.2x |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 8.4% | 15.1% |
| Last close | $224.41 | $88.24 |
| P/E at the last close | — | 24.1× |
| Insider trades, last 12 months | sold $80.3 million | bought $1.1 million, sold $4.3 million |
| Piotroski F-score | — | 7 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
GlaukosTransMedics Group
Operating margin
Percent of revenue
GlaukosTransMedics Group
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
GlaukosTransMedics Group
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Glaukos and TransMedics Group pages.